Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | UBE2M | P61081 | 8/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24366681 | 1.00 | NPC1 (0.58) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL18711260 | 0.85 | UBE2M (0.60) | MAPTTP53LMNAUBE2MDCUN1D1 | |
| SCHEMBL30753156 | 0.83 | NPC1 (0.65) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL7931954 | 0.82 | UBE2M (0.70) | MAPTTP53POLBHTTLMNA | |
| SCHEMBL29981203 | 0.80 | NPC1 (0.61) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL24367499 | 0.80 | NPC1 (0.61) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL24365278 | 0.80 | NPC1 (0.64) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL31145058 | 0.80 | NPC1 (0.64) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL18657533 | 0.80 | UBE2M (0.60) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL24366675 | 0.78 | UBE2M (0.45) | MAPTTP53POLBHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | NPC1 24/4885RAB9A 420/4885MAPT 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.